AstraZeneca/£AZN

07:00
09:10
11:15
13:25
15:30
1D1W1MYTD1Y5YMAX

About AstraZeneca

A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (about 40% of total revenue), cardiovascular, renal, and metabolic (25%), rare disease (17%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one third of its sales.

Ticker

£AZN

Primary listing

LSE

Industry

Pharmaceuticals

Employees

94,300

ISIN

GB0009895292

AstraZeneca Metrics

BasicAdvanced
£164B
28.66
£3.68
0.18
£2.46
2.33%

What the Analysts think about AstraZeneca

Analyst ratings (Buy, Hold, Sell) for AstraZeneca stock.

Bulls say / Bears say

AstraZeneca's triple-combination inhaler, Breztri Aerosphere, achieved all main objectives in late-stage clinical trials for treating uncontrolled asthma, potentially expanding its market share in respiratory treatments. (reuters.com)
The company raised its 2024 sales and profit forecast due to strong demand for cancer and rare disease medicines, indicating robust growth in key therapeutic areas. (reuters.com)
AstraZeneca plans to invest $2.5 billion in a new research center in Beijing, reflecting confidence in the Chinese market and commitment to expanding its R&D capabilities. (fastbull.com)
AstraZeneca's first-quarter revenues fell short of analyst expectations, leading to a share price decline of more than 4%, raising concerns about its financial performance. (reuters.com)
The company faces potential fines of up to $4.5 million in China for unpaid import taxes, which could impact its financials and operations in a key market. (reuters.com)
Despite raising its 2024 outlook, AstraZeneca's shares have fallen nearly 6% this year due to concerns over its Chinese business amid investigations, affecting investor confidence. (reuters.com)
Data summarised monthly by Lightyear AI. Last updated on 22 May 2025.

AstraZeneca Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

AstraZeneca Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.

Buy £AZN

Sign up or log in to buy
Capital at risk
Market open

Upcoming events

No upcoming events
FAQs